{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:56:16Z","timestamp":1789408576216,"version":"build-2803163510"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      To evaluate the prognostic value of the baseline SUVmax of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT in extranodal natural killer\/T-cell lymphoma (NKTCL) patients.\n                    <\/jats:p>\n                    <jats:p>\n                      From January 2010 to December 2015, 141 extranodal NKTCL patients with staging\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT scan were divided into two group based on SUVmax cutoff value obtained from operating characteristic (ROC) curves. All the patients received radiotherapy, chemotherapy or chemoradiation. Survival analysis was performed on the basis of SUVmax.\n                    <\/jats:p>\n                    <jats:p>\n                      The median baseline SUVmax of the tumors was 11.67 (range 2.6\u201334.6). The ROC curves showed that the optimal cutoff of the baseline SUVmax was 9.65. The patients were divided into two groups: low SUV group (SUVmax\u200a&lt;\u200a9.65) and high SUV group (SUVmax\u200a\u2265\u200a9.65). Patients in high SUV group were more likely to have invasive disease outside the nasal cavity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.001), poorer ECOG scores (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.012) and higher LDH levels (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.034). The univariate survival analyses indicated that high SUVmax was a poor prognostic factor for overall survival (OS,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.038), progression free survival (PFS,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.006) and distant relapse free survival (DRFS,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.001), but not for local recurrence free survival (LRFS,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&gt;\u200a.05). These results were consistent with that of the survival analyses using the Kaplan\u2013Meier method. The multivariate survival analyses showed that the baseline SUVmax was no longer a prognostic factor for OS (HR 1.99, 95% CI 0.81\u20134.88,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.135), but it still indicated worse PFS (HR 2.6, 95% CI 1.24\u20135.46,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.012) and DRFS (HR 4.58, 95% CI 1.83\u201311.46,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.001) independent of other variables.\n                    <\/jats:p>\n                    <jats:p>\n                      For extranodal NKTCL patients, a higher baseline SUVmax of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT was associated with more aggressive clinical features. An SUVmax\u200a\u2265\u200a9.65 was an independent poor prognostic factor for DRFS and PFS. Thus, the baseline SUVmax may be a valuable tool to help identify patients with a high risk of disease progression.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000022143","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T02:03:44Z","timestamp":1599703424000},"page":"e22143","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer\/T-cell lymphoma"],"prefix":"10.1097","volume":"99","author":[{"given":"Xianwu","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Radiology, Municipal Hospital Affiliated to Medical School of Taizhou University, Taizhou, Zhejiang"},{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Municipal Hospital Affiliated to Medical School of Taizhou University, Taizhou, Zhejiang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Medical College, Fudan University"},{"name":"Department of Nuclear Medicine, Fudan University Shanghai Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Medical College, Fudan University"},{"name":"Department of Nuclear Medicine, Fudan University Shanghai Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Medical College, Fudan University"},{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, PR China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9936-4194","authenticated-orcid":false,"given":"Xuejun","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"R1-20251104","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/annonc\/mdi037","article-title":"Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years","volume":"16","author":"Au","year":"2005","journal-title":"Ann Oncol"},{"key":"R2-20251104","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-017-0452-9","article-title":"The diagnosis and management of NK\/T-cell lymphomas","volume":"10","author":"Tse","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R3-20251104","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","article-title":"Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma","volume":"24","author":"Li","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-20251104","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"key":"R5-20251104","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00277-014-2137-6","article-title":"Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK\/T cell lymphoma: CISL08-01 phase II study","volume":"93","author":"Kim","year":"2014","journal-title":"Ann Hematol"},{"key":"R6-20251104","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"key":"R7-20251104","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"R8-20251104","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211","volume":"27","author":"Yamaguchi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R9-20251104","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.bjc.6602502","article-title":"Nasal-type NK\/T cell lymphoma: clinical features and treatment outcome","volume":"92","author":"Lee","year":"2005","journal-title":"Br J Cancer"},{"key":"R10-20251104","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"R11-20251104","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/leu.2013.212","article-title":"Quantification of circulating Epstein-Barr virus DNA in NK\/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance","volume":"28","author":"Kwong","year":"2014","journal-title":"Leukemia"},{"key":"R12-20251104","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"key":"R13-20251104","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"R14-20251104","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","article-title":"The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi","volume":"24","author":"Luminari","year":"2013","journal-title":"Ann Oncol"},{"key":"R15-20251104","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2011.38.2648","article-title":"Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab","volume":"30","author":"Safar","year":"2012","journal-title":"J Clin Oncol"},{"key":"R16-20251104","doi-asserted-by":"crossref","first-page":"e0194435","DOI":"10.1371\/journal.pone.0194435","article-title":"Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET\/CT parameters in extranodal natural killer\/T-cell lymphoma: A meta-analysis","volume":"13","author":"Wang","year":"2018","journal-title":"PLoS One"},{"key":"R17-20251104","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1097\/MD.0000000000000258","article-title":"Utility of PET\/CT in the diagnosis and staging of extranodal natural killer\/T-cell lymphoma: a systematic review and meta-analysis","volume":"93","author":"Zhou","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"R18-20251104","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2967\/jnumed.108.053355","article-title":"Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer\/T-cell lymphomas of the head and neck","volume":"49","author":"Suh","year":"2008","journal-title":"J Nucl Med"},{"key":"R19-20251104","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00259-013-2443-6","article-title":"Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on (1)(8)F-FDG PET\/CT in patients with extranodal NK\/T-cell lymphoma","volume":"40","author":"Kim","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R20-20251104","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12032-012-0339-0","article-title":"Predictive value of pretreatment positron emission tomography\/computed tomography in patients with newly diagnosed extranodal natural killer\/T-cell lymphoma","volume":"30","author":"Bai","year":"2013","journal-title":"Med Oncol"},{"key":"R21-20251104","doi-asserted-by":"crossref","first-page":"41057","DOI":"10.1038\/srep41057","article-title":"Utility of baseline, interim and end-of-treatment (18)F-FDG PET\/CT in extranodal natural killer\/T-cell lymphoma patients treated with L-asparaginase\/pegaspargase","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"key":"R22-20251104","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12149-015-0964-8","article-title":"Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET\/CT in extranodal natural killer\/T-cell lymphoma, nasal type","volume":"29","author":"Jiang","year":"2015","journal-title":"Ann Nucl Med"},{"key":"R23-20251104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjoto.2017.10.009","article-title":"Prognostic significance of standardized uptake value on F18-FDG PET\/CT in patients with extranodal nasal type NK\/T cell lymphoma: a multicenter, retrospective analysis","volume":"39","author":"Pak","year":"2018","journal-title":"Am J Otolaryngol"},{"key":"R24-20251104","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2003-05-1401","article-title":"Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index","volume":"103","author":"Chim","year":"2004","journal-title":"Blood"},{"key":"R25-20251104","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ejca.2005.03.010","article-title":"Extranodal nasal type NK\/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy","volume":"41","author":"Lee","year":"2005","journal-title":"Eur J Cancer"},{"key":"R26-20251104","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2012.09.011","article-title":"Clinical value of metabolic tumor volume by PET\/CT in extranodal natural killer\/T cell lymphoma","volume":"37","author":"Song","year":"2013","journal-title":"Leuk Res"},{"key":"R27-20251104","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-20251104","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/RLU.0000000000000892","article-title":"The Deauville 5-point scale improves the prognostic value of interim FDG PET\/CT in extranodal natural killer\/T-cell lymphoma","volume":"40","author":"Jiang","year":"2015","journal-title":"Clin Nucl Med"},{"key":"R29-20251104","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/MNM.0000000000000731","article-title":"Predictive approaches for post-therapy PET\/CT in patients with extranodal natural killer\/T-cell lymphoma: a retrospective study","volume":"38","author":"Jiang","year":"2017","journal-title":"Nucl Med Commun"},{"key":"R30-20251104","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/S2352-3026(15)00002-2","article-title":"Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer\/T-cell lymphoma, nasal type: a multicentre, retrospective analysis","volume":"2","author":"Kim","year":"2015","journal-title":"Lancet Haematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:00:44Z","timestamp":1762243244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":30,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022143","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,11]]},"assertion":[{"value":"2020-05-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}